3 US Defensive Stocks Built For Inflation And Rate Uncertainty

With inflation still running above the Fed’s 2% target and rate expectations shifting with every new comment from policymakers, many investors are rethinking how to position their portfolios. Defensive sector stocks can sometimes offer a steadier ride when interest rates and bond yields are in focus, because these companies sell essential goods and services that people tend to keep buying. This article looks at three U.S. defensive stocks that are closely exposed to the latest Federal Reserve signals and inflation trends, and explains why some investors may see them as candidates to watch or avoid right now.

Overview: AMN Healthcare Services is a Dallas based company that helps hospitals, clinics and schools keep critical roles filled by providing travel nurses, allied health professionals, physicians, interim leaders and technology enabled workforce tools across the U.S.

Operations: AMN Healthcare Services generates most of its US$3.4b revenue in the United States, led by Nurse and Allied Solutions at about US$2.4b, followed by Physician and Leadership Solutions at about US$0.7b and Technology and Workforce Solutions at about US$0.4b.

Market Cap: US$1.3b

Investors looking at AMN Healthcare Services in a period of persistent inflation and rate uncertainty may be drawn to its role in keeping essential healthcare staffing running, even when hospitals are tightening budgets. The company sits at the intersection of rising wage pressure, ongoing clinician shortages and client interest in flexible staffing models, which creates both pricing risk and the potential for higher value tech driven services. Recent attention on AI enabled platforms, acquisitions in digital staffing and improving profitability metrics highlight why some see more to this story than a traditional agency recruiter. The key question is whether structural demand and technology can offset funding pressure, revenue headwinds and balance sheet risk over the next few years.

AMN Healthcare Services sits where wage pressure, staffing shortages and new tech platforms intersect. Many investors still underestimate this dynamic. To see how those forces align in one place, review the analysis report for AMN Healthcare Services

Overview: Edwards Lifesciences develops medical devices for patients with advanced heart disease, focusing on minimally invasive transcatheter valves and surgical heart valve solutions that replace or repair damaged heart valves. Its products are used globally in hospitals to support life saving cardiovascular procedures that are often not easily postponed.

Operations: Edwards Lifesciences generates about US$6.5b in annual revenue from medical products, with around US$3.8b from the United States and the rest spread across Europe, Japan and other international markets.

Market Cap: US$50.0b

Edwards Lifesciences can interest investors who want exposure to essential heart therapies that often remain in demand even when higher inflation, rising bond yields and potential Fed rate hikes unsettle markets. The company is leaning into transcatheter valves and next generation structural heart devices, which sit behind its guidance for sales growth and a recovery in profitability after a period of margin pressure and a large one off loss. At the same time, insider selling, tariff headwinds, acquisition related dilution and a relatively high P/E create real execution risk. The key consideration is whether the mix of new therapies, possible Medicare coverage changes and long term earnings ambitions is strong enough to justify that optimism.

Edwards Lifesciences is leaning hard into transcatheter growth while margin pressure, tariffs and acquisition effects still hang over the story. Get the full context in the 2 key rewards and 3 important warning signs

Overview: Surgery Partners operates a nationwide network of outpatient surgical centers and surgical hospitals, focusing on non emergency procedures in specialties such as orthopedics, pain management, ophthalmology, gastroenterology and general surgery, along with physician practices, urgent care and anesthesia services.

Operations: Surgery Partners generates about US$3.3b in revenue from its surgical facilities and ancillary services, all of which currently comes from the United States.

Market Cap: US$2.1b

Investors watching Surgery Partners in a period of higher rates and volatile bond markets may see a business that combines essential healthcare demand with a complex balance sheet story. The stock trades at a low P/S of about 0.6x and has earnings that analysts expect to turn positive, yet it still reports losses, carries meaningful net debt and relies entirely on external borrowing. Its outpatient model is exposed to regulatory change and payer pressure. Management is working on margin repair, payer mix reset and portfolio reshaping, including recent asset sale agreements. The key consideration is whether this mix of essential procedures, margin initiatives and interest rate risk management is sufficient to support current expectations for a shift to profitability.

Surgery Partners looks like an earnings story waiting to turn, with a low P/S, essential procedures, and active portfolio moves. See how those pieces line up in the analyst forecasts for Surgery Partners and what could still surprise the market.

The three defensive stocks covered here are only a starting point. The full U.S. Defensive Sector Stocks screen uncovers 37 more companies with similarly detailed stories worth your attention through the U.S. Defensive Sector Stocks screener. Use Simply Wall St to identify and analyze the specific catalysts, risk flags and narrative drivers that matter most to you so you can focus on the highest conviction ideas in this group.

Take Control of Your Investment Journey

If Surgery Partners or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point.
Once you’ve made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates.
Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives.
By uncovering hidden catalysts and risks early, you’ll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives For Your Curiosity?

Some of the most interesting stocks may move while attention is elsewhere. Look for fresh momentum, identify potential breakouts that are still under the radar, and consider opportunities at an early stage.

• Focus on companies where dependable cash flows align with solid balance sheets by scanning the curated 55 high quality undervalued stocks before broader attention turns to potential breakout stories.
• Identify fast-moving AI opportunities with demonstrated earnings strength by reviewing the hand picked 70 profitable AI stocks that aren’t just burning cash while expectations are still forming and prices may not yet fully reflect changing conditions.
• Monitor resilient operators designed to handle shocks by using the focused 81 resilient stocks with low risk scores ahead of periods when market stress may reveal which businesses are maintaining stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com